LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.330
-0.020 (-1.48%)
Mar 13, 2025, 4:00 PM EST - Market closed
LAVA Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for LAVA Therapeutics stock have an average target of 3.17, with a low estimate of 1.50 and a high estimate of 6.00. The average target predicts an increase of 138.35% from the current stock price of 1.33.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for LAVA Therapeutics stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $2 → $1.5 | Strong Buy → Hold | Downgrades | $2 → $1.5 | +12.78% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $2 | Strong Buy | Maintains | $6 → $2 | +50.38% | Dec 20, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $11 → $2 | Buy → Hold | Downgrades | $11 → $2 | +50.38% | Dec 12, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +351.13% | Dec 11, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $6 | Buy | Reiterates | $6 | +351.13% | Aug 21, 2024 |
Financial Forecast
Revenue This Year
7.90M
from 6.77M
Increased by 16.68%
Revenue Next Year
n/a
from 7.90M
EPS This Year
-1.17
from -1.57
EPS Next Year
-1.38
from -1.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 12.6M | n/a | n/a | |||
| Avg | 7.9M | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 86.0% | - | - | |||
| Avg | 16.7% | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.99 | -0.96 | -0.62 | |||
| Avg | -1.17 | -1.38 | -1.06 | |||
| Low | -1.48 | -1.55 | -1.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.